Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension (Q44961465)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension (English)

1 reference

Europe PubMed Central

7 December 2017

1 reference

based on heuristic

inferred from title

Kristine Ensrud

1

object named as

Kristine E Ensrud

1 reference

Europe PubMed Central

7 December 2017

12

object named as

Dennis M Black

1 reference

Europe PubMed Central

7 December 2017

3

object named as

Ann Schwartz

1 reference

Europe PubMed Central

7 December 2017

Douglas C Bauer

5

object named as

Douglas C Bauer

1 reference

Europe PubMed Central

7 December 2017

Arthur C. Santora

4

object named as

Arthur C Santora

1 reference

Europe PubMed Central

7 December 2017

Marc C. Hochberg

9

object named as

Marc C Hochberg

1 reference

Europe PubMed Central

7 December 2017

Elizabeth Barrett-Connor

2

object named as

Elizabeth L Barrett-Connor

1 reference

Europe PubMed Central

7 December 2017

Adrianne C Feldstein

7

object named as

Adrianne Feldstein

1 reference

Europe PubMed Central

7 December 2017

William Haskell

8

object named as

William L Haskell

1 reference

Europe PubMed Central

7 December 2017

author name string

Shailaja Suryawanshi

6

1 reference

Europe PubMed Central

7 December 2017

James C Torner

10

1 reference

Europe PubMed Central

7 December 2017

Antonio Lombardi

11

1 reference

Europe PubMed Central

7 December 2017

Fracture Intervention Trial Long-Term Extension Research Group

13

1 reference

Europe PubMed Central

7 December 2017

publication date

29 March 2004

1 reference

Europe PubMed Central

7 December 2017

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

7 December 2017

19

1 reference

Europe PubMed Central

7 December 2017

8

1 reference

Europe PubMed Central

7 December 2017

1259-1269

1 reference

Europe PubMed Central

7 December 2017

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Design of the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Bone microdamage and skeletal fragility in osteoporotic and stress fractures

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Timing of estrogen replacement therapy for optimal osteoporosis prevention.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Osteoporosis and fractures in postmenopausal women using estrogen.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Acid peptic disease in the elderly

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Bone matters: are density increases necessary to reduce fracture risk?

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Identifiers

10.1359/JBMR.040326

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44961465&oldid=2083588474"